INFLARX NV (IFRX) Stock Price, Forecast & Analysis
NASDAQ:IFRX • NL0012661870
IFRX Key Statistics, Chart & Performance
The current stock price of IFRX is 0.9429 USD. In the past month the price decreased by -5.27%. In the past year, price decreased by -36.55%.
IFRX Technical Analysis
IFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX may be in some trouble as it scores bad on both profitability and health.
IFRX Financial Highlights
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by 38.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.55% | ||
| ROE | -88.4% | ||
| Debt/Equity | 0.02 |
IFRX Forecast & Estimates
14 analysts have analysed IFRX and the average price target is 10.93 USD. This implies a price increase of 1059.04% is expected in the next year compared to the current price of 0.9429.
For the next year, analysts expect an EPS growth of 12.2% and a revenue growth -77.89% for IFRX
IFRX Ownership
IFRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.66 | 403.74B | ||
| AMGN | AMGEN INC | 17.04 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.48 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.69 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.96 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.28 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.55 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.96 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IFRX
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Company Info
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
INFLARX NV / IFRX FAQ
Can you describe the business of INFLARX NV?
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
What is the stock price of INFLARX NV today?
The current stock price of IFRX is 0.9429 USD. The price increased by 6.92% in the last trading session.
What is the dividend status of INFLARX NV?
IFRX does not pay a dividend.
How is the ChartMill rating for INFLARX NV?
IFRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is INFLARX NV (IFRX) stock traded?
IFRX stock is listed on the Nasdaq exchange.
What is the employee count for IFRX stock?
INFLARX NV (IFRX) currently has 74 employees.
Can you provide the market cap for INFLARX NV?
INFLARX NV (IFRX) has a market capitalization of 63.88M USD. This makes IFRX a Micro Cap stock.